Laboratory Developed Tests Market Size to Reach USD 26.97 Billion by 2034 as Specialized Testing Demand Rises

The laboratory developed tests market stood at USD 14.16 billion in 2025 and is expected to reach USD 26.97 billion in 2034. The market is projected to grow at a CAGR of 7.4% from 2026 to 2034. Laboratory developed tests, or LDTs, are designed for use in the laboratory that designs them. Such tests are mostly used by clinicians who need tests for specific biomarkers, diseases, or patient populations that have no commercial test options available.

There are many laboratory methods that are represented in the LDT sphere. Among them, molecular diagnostics, immunoassays, microbiology, and clinical diagnostics are the key ones. In addition, applications include oncology, genetic conditions, infectious diseases, and metabolic disorders. Increasing interest in more targeted information is increasing the scope of laboratory tests.

Chronic Disease and Precision Medicine Support Demand

The increasing prevalence of chronic diseases is adding to the need for diagnostic testing. Cancer, in particular, often requires more than routine laboratory analysis. Molecular and genetic testing can provide information about disease characteristics that may affect diagnosis or treatment decisions.

Rare diseases present a different testing need. Many involve uncommon genetic variants and have relatively small patient populations. Commercial tests may not be available for every condition. Clinical laboratories can develop their own methods when a particular testing requirement is not covered.

Precision medicine is placing yet another level of demand on this area. Treatment modalities are chosen based on traits that are identified through diagnostic testing procedures. The use of diagnostic testing procedures is therefore becoming more relevant to patient care decisions.

The molecular diagnostics market also stands to benefit from the increasing use of genomics and molecular data in clinical practice. This creates a larger scope for LDTs, especially where testing specifications are highly specialized.

Molecular Testing Expands the Scope of LDTs

Molecular diagnostics has become a significant part of the laboratory developed tests market. These methods allow laboratories to look for genetic changes, disease-related markers, and infectious organisms.

The range of available molecular techniques has also expanded. Next-generation sequencing can examine multiple genetic targets in a single analysis, while targeted methods can focus on a specific mutation or biomarker. Laboratories can select the approach that fits the clinical question and sample type.

This flexibility is useful in oncology and inherited disease testing. It also matters when new biomarkers enter clinical research and begin moving toward patient testing. Developments in molecular testing are therefore closely connected with the [advanced cancer diagnostics market].

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: Laboratory Developed Tests Market Report

FDA LDT Rule Vacatur Changes the U.S. Market

Regulation remains an important consideration for the U.S. LDT market. In May 2024, the FDA issued a final rule that revised the regulatory framework for in vitro diagnostic products, including those manufactured by laboratories. The rule also set out a plan to phase out the agency's general enforcement discretion for LDTs.

That position changed in 2025. On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the rule. The FDA did not appeal the decision. The agency subsequently removed the regulatory changes introduced by the 2024 rule in September 2025. (source: congress.gov)

For laboratories, the decision removed the additional FDA device requirements that had been anticipated under the vacated rule. CLIA continues to govern the quality and operational requirements of clinical laboratories. State laws and other federal requirements may also apply depending on the test and its use.

The regulatory outlook is therefore different from the one laboratories faced after the 2024 final rule. Further policy changes could still alter the market environment.

Oncology and Genetic Disorders Remain Key Applications

One of the well-established areas of use for LDTs is oncology. The analysis of mutations or other characteristics of certain molecules is required for cancer testing. Tests are created by laboratories depending on these demands, in case no commercial testing method fits the requirement.

Genetic disorders also involve special analysis. Genetic testing helps find out which variants are related to certain hereditary diseases and supports physicians in the process of diagnosis. This issue is especially topical regarding rare diseases.

The development of the rare disease genetic testing market shows that genetic analysis is increasingly used in diagnostics. With the discovery of new variants associated with certain diseases, there are new possibilities for test development.

Competitive Landscape

The laboratory developed tests market includes large reference laboratories, hospital-based testing providers, specialty laboratories, and companies supplying diagnostic technologies. Large laboratory networks have established infrastructure and broad clinical test menus. Specialty providers tend to compete in narrower fields where technical expertise is important. Diagnostic technology companies contribute the instruments and platforms used for many molecular and biomarker tests.

Commercial diagnostic products remain an alternative to LDTs. The distinction is most relevant when a laboratory needs a test tailored to a particular clinical requirement. In such cases, the ability to develop and validate a laboratory-specific method can influence the choice of testing approach.

Market Outlook

Demand for specialized diagnostics is likely to remain a central factor shaping the laboratory developed tests market through 2034. Molecular testing should continue to account for a substantial share of LDT activity, while oncology and genetic disorders offer important areas for test development.

The U.S. regulatory framework will remain closely watched following the vacatur of the FDA's 2024 rule. At the same time, advances in biomarker discovery and precision medicine should continue to introduce new testing requirements. Laboratories that can respond to these needs while maintaining consistent test performance will have scope to expand their LDT portfolios.

Laboratory Developed Tests Market Segmentation

By End Use: Hospital Laboratories | Private/Independent Reference Laboratories | Specialty Diagnostic Laboratories | Other (Academic/Research)

By Region: North America (U.S., Canada) | Europe (UK, Germany, France, Italy, Spain, Netherlands, Russia, Rest of Europe) | Asia Pacific (China, India, Japan, Malaysia, Indonesia, South Korea, Rest of Asia Pacific) | Latin America (Brazil, Mexico, Argentina, Rest of Latin America) | Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of Middle East & Africa)